Pharmaceutical Partnerships

Business

Uber's Autonomous Ambitions Face Reality Check as New Jersey Ruling Reclassifies Drivers

Uber Technologies is aggressively expanding its autonomous vehicle ecosystem through new partnerships and its AV Labs division, even as a landmark New Jersey court decision threatens to upend its core gig-economy labor model, setting the stage for a pivotal clash between its future vision and present-day regulatory challenges.

Jan 30, 2026

Business

Bank of America Bullish on Apellis, Upgrades to 'Buy' on Strong Drug Launch and Kidney Disease Prospects

Bank of America has upgraded Apellis Pharmaceuticals (APLS) to 'Buy,' citing robust early adoption of its drug Empaveli and significant undervaluation of its potential in treating rare kidney diseases, despite a more cautious outlook from Wells Fargo.

Jan 30, 2026

Business

AstraZeneca Bets $1.2 Billion on CSPC's Weight-Loss Drug Pipeline in Major China Deal

British pharmaceutical giant AstraZeneca has entered a strategic partnership with China's CSPC Pharmaceutical, committing over $1 billion upfront to co-develop next-generation obesity therapies, signaling intensified competition in the lucrative global weight-loss drug market.

Jan 30, 2026

Business

Grab Appoints New Independent Director as It Doubles Down on Grocery, Fintech and Autonomous Vehicle Ambitions

Southeast Asian super app Grab Holdings has appointed Laura Franco to its board, succeeding the retiring Ng Shin Ein. The move signals a governance refresh aimed at steering the company's aggressive expansion into on-demand grocery, financial technology, and next-generation mobility partnerships.

Jan 30, 2026

Business

Regeneron's Stock Slump: A Buying Opportunity or a Sign of Deeper Trouble?

Regeneron Pharmaceuticals' shares have softened in recent weeks, lagging behind broader market gains. A deep dive into valuation metrics, including DCF analysis and P/E ratios, suggests the biotech giant may be significantly undervalued. We examine the numbers behind the headlines and what they mean for investors.

Jan 30, 2026

Business

Qualcomm's Strategic Pivot: From Mobile Dominance to AI at the Edge

Qualcomm is aggressively diversifying its business beyond smartphones, forging new partnerships in drone security and legal tech to establish its Snapdragon platform as a cornerstone for on-device AI and edge computing.

Jan 30, 2026

Business

Eli Lilly Bets Nearly $2 Billion on Repertoire Immune Medicines to Pioneer Next-Generation Autoimmune Therapies

Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.

Feb 2, 2026

Business

Defense Spending Nears $1 Trillion as AI Chip Integration Reshapes Military Tech

Rising global defense budgets are accelerating the adoption of artificial intelligence in military systems, with companies racing to develop advanced sensing and threat-detection capabilities through strategic partnerships and acquisitions.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

D-Wave Quantum's 38% Plunge: A Buying Opportunity or a Value Trap?

Despite a meteoric long-term rise, D-Wave Quantum's recent sharp decline highlights the extreme risks and towering valuations inherent in the speculative quantum computing sector. Investors face a critical decision.

Feb 2, 2026

Business

Beyond the Hype: How a Power Giant is Fueling the AI Revolution

As tech giants pour trillions into AI infrastructure, the insatiable demand for electricity is creating a new class of winners. NextEra Energy, America's largest utility, is emerging as a critical, if unexpected, backbone of the artificial intelligence boom through strategic partnerships with Alphabet and Meta.

Feb 2, 2026

Business

Samsung Unveils Olympic Edition Z Flip7 and Enhanced Privacy Tools, Spotlighting Strategic Moves Beyond Hardware

Samsung Electronics has launched a special edition Galaxy Z Flip7 for the 2026 Winter Olympics, packed with AI-powered translation and athlete-centric features, while also previewing new on-screen privacy controls designed to thwart 'shoulder surfing'. These dual announcements underscore the tech giant's push to blend high-profile partnerships with user-centric innovation as it seeks to differentiate in a competitive market.

Feb 2, 2026

Business

Idorsia's Latin American Gambit: QUVIVIQ Deal with EMS Signals Strategic Shift Amid Pipeline Scrutiny

Idorsia's exclusive licensing agreement with EMS to commercialize insomnia drug QUVIVIQ across Latin America marks a key step in its global expansion. The deal, involving $20 million in milestones and royalties, arrives as long-term data for its Fabry disease candidate lucerastat puts the spotlight on the company's broader late-stage pipeline and persistent financial pressures.

Feb 2, 2026

Business

Danaher Forges Strategic Alliance with Automata, Accelerating AI-Powered Laboratory Automation

Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.

Jan 31, 2026

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Jan 31, 2026

Business

Pfizer's $23 Billion Oncology Bet: CEO Albert Bourla's Post-Pandemic Quest to 'Save the World from Cancer'

After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.

Jan 30, 2026

Business

Credit Acceptance Beats Q4 Estimates on Tech Push and Dealer Focus

Credit Acceptance (CACC) posted strong fourth-quarter results, surpassing revenue and profit forecasts. The auto finance firm credits its performance to new digital tools for dealers and strategic investments in AI, aiming to deepen partnerships in a competitive market.

Jan 30, 2026

Business

Dolby Q4 Earnings: Automotive and Streaming Gains Drive Revenue Beat, But Margin Pressures Loom

Dolby Laboratories surpassed Wall Street's Q4 revenue and profit forecasts, fueled by strong growth in automotive partnerships and streaming adoption. However, a year-over-year sales decline and contracting operating margins highlight the challenges of shifting product mix and restructuring costs.

Jan 30, 2026

Business

Uber Doubles Down on Autonomous Future with $1B Waabi Bet, Expanding Robotaxi Ambitions

Uber's strategic investment in self-driving startup Waabi, founded by its former AI chief, signals a major push into robotaxis. The $1 billion deal underscores Uber's sprawling portfolio of over 20 AV partnerships, raising questions about its 'bet-on-everything' approach in the high-stakes race for autonomy.

Jan 30, 2026

Business

Eli Lilly Bets $3.5 Billion on Pennsylvania as Pharma Giants Shift Production Stateside

Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.

Jan 30, 2026